Loading…
Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors
This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with Y-[DOTA , D-Phe , Tyr ]-octreotate. CgA was determined before pe...
Saved in:
| Published in: | Future oncology (London, England) England), 2017-05, Vol.13 (12), p.1069-1079 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33 |
| container_end_page | 1079 |
| container_issue | 12 |
| container_start_page | 1069 |
| container_title | Future oncology (London, England) |
| container_volume | 13 |
| creator | Rogowski, Wojciech Wachu a, Ewa Lewczuk, Anna Kolesi ska- wik a, Agnieszka I ycka- wieszewska, Ewa Sul yc-Bielicka, Violetta wik a, Jaros aw B |
| description | This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with
Y-[DOTA
, D-Phe
, Tyr
]-octreotate.
CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of
Y-[DOTA
, D-Phe
, Tyr
]-octreotate. The primary end point was overall survival.
Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.
Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold. |
| doi_str_mv | 10.2217/fon-2016-0455 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1861566955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275854923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33</originalsourceid><addsrcrecordid>eNp1kcFPHCEUh0ljU3XtsVdD0ksvU4GBYeZoN1abmHipZ8I-Hlu2O7CFmYP_vUxWPTTxBLx8fHn5_Qj5wtl3Ibi-8ik2gvGuYVKpD-SMaymbvmX8pN6lHpquG-QpOS9lx5jUrWKfyKno2aC0YGck_bAF9yEihT85jWmbbQyRXlMbHQ1Toe4p2jFAoTYjPeS0jalMAeho81_MhVZ4a8uUE8YJczrYCBntQkScl6lLkBf_NI8plwvy0dt9wc8v54o8_rz5vb5r7h9uf62v7xtoNZ8aKdChcGA7LvQwQO9B6430YHvVtRvgfkDueq2tU45x2WrhOVjGvOIbi227It-O3rryvxnLZMZQAPd7GzHNxfC-46pGo1RFv_6H7tKcY93OCKFVr-QgFmFzpCCnUjJ6c8ihhvBkODNLE6Y2YZYmzNJE5S9frPNmRPdGv0ZfgeEI-HmaMxYIGAHN8VV_BKipvSN_BmU1mlI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275854923</pqid></control><display><type>article</type><title>Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors</title><source>PubMed Central</source><creator>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Kolesi ska- wik a, Agnieszka ; I ycka- wieszewska, Ewa ; Sul yc-Bielicka, Violetta ; wik a, Jaros aw B</creator><creatorcontrib>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Kolesi ska- wik a, Agnieszka ; I ycka- wieszewska, Ewa ; Sul yc-Bielicka, Violetta ; wik a, Jaros aw B</creatorcontrib><description>This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with
Y-[DOTA
, D-Phe
, Tyr
]-octreotate.
CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of
Y-[DOTA
, D-Phe
, Tyr
]-octreotate. The primary end point was overall survival.
Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.
Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2016-0455</identifier><identifier>PMID: 28095720</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Biomarkers ; Biomarkers, Tumor ; Cancer therapies ; Chemotherapy ; chromogranin A ; Chromogranin A - blood ; Clinical medicine ; Cluster analysis ; Combined Modality Therapy ; Disease ; Disease Progression ; Female ; Humans ; Intestinal Neoplasms - blood ; Intestinal Neoplasms - diagnosis ; Intestinal Neoplasms - mortality ; Intestinal Neoplasms - therapy ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Neuroendocrine tumors ; Neuroendocrine Tumors - blood ; Neuroendocrine Tumors - diagnosis ; Neuroendocrine Tumors - mortality ; Neuroendocrine Tumors - therapy ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - therapy ; Peptides ; Prognosis ; Radiation therapy ; radionuclide therapy ; Stomach Neoplasms - blood ; Stomach Neoplasms - diagnosis ; Stomach Neoplasms - mortality ; Stomach Neoplasms - therapy ; Studies ; survival ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2017-05, Vol.13 (12), p.1069-1079</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd May 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33</citedby><cites>FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28095720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachu a, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Kolesi ska- wik a, Agnieszka</creatorcontrib><creatorcontrib>I ycka- wieszewska, Ewa</creatorcontrib><creatorcontrib>Sul yc-Bielicka, Violetta</creatorcontrib><creatorcontrib>wik a, Jaros aw B</creatorcontrib><title>Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with
Y-[DOTA
, D-Phe
, Tyr
]-octreotate.
CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of
Y-[DOTA
, D-Phe
, Tyr
]-octreotate. The primary end point was overall survival.
Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.
Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.</description><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>chromogranin A</subject><subject>Chromogranin A - blood</subject><subject>Clinical medicine</subject><subject>Cluster analysis</subject><subject>Combined Modality Therapy</subject><subject>Disease</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Intestinal Neoplasms - blood</subject><subject>Intestinal Neoplasms - diagnosis</subject><subject>Intestinal Neoplasms - mortality</subject><subject>Intestinal Neoplasms - therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - blood</subject><subject>Neuroendocrine Tumors - diagnosis</subject><subject>Neuroendocrine Tumors - mortality</subject><subject>Neuroendocrine Tumors - therapy</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Peptides</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>radionuclide therapy</subject><subject>Stomach Neoplasms - blood</subject><subject>Stomach Neoplasms - diagnosis</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - therapy</subject><subject>Studies</subject><subject>survival</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kcFPHCEUh0ljU3XtsVdD0ksvU4GBYeZoN1abmHipZ8I-Hlu2O7CFmYP_vUxWPTTxBLx8fHn5_Qj5wtl3Ibi-8ik2gvGuYVKpD-SMaymbvmX8pN6lHpquG-QpOS9lx5jUrWKfyKno2aC0YGck_bAF9yEihT85jWmbbQyRXlMbHQ1Toe4p2jFAoTYjPeS0jalMAeho81_MhVZ4a8uUE8YJczrYCBntQkScl6lLkBf_NI8plwvy0dt9wc8v54o8_rz5vb5r7h9uf62v7xtoNZ8aKdChcGA7LvQwQO9B6430YHvVtRvgfkDueq2tU45x2WrhOVjGvOIbi227It-O3rryvxnLZMZQAPd7GzHNxfC-46pGo1RFv_6H7tKcY93OCKFVr-QgFmFzpCCnUjJ6c8ihhvBkODNLE6Y2YZYmzNJE5S9frPNmRPdGv0ZfgeEI-HmaMxYIGAHN8VV_BKipvSN_BmU1mlI</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Rogowski, Wojciech</creator><creator>Wachu a, Ewa</creator><creator>Lewczuk, Anna</creator><creator>Kolesi ska- wik a, Agnieszka</creator><creator>I ycka- wieszewska, Ewa</creator><creator>Sul yc-Bielicka, Violetta</creator><creator>wik a, Jaros aw B</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors</title><author>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Kolesi ska- wik a, Agnieszka ; I ycka- wieszewska, Ewa ; Sul yc-Bielicka, Violetta ; wik a, Jaros aw B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>chromogranin A</topic><topic>Chromogranin A - blood</topic><topic>Clinical medicine</topic><topic>Cluster analysis</topic><topic>Combined Modality Therapy</topic><topic>Disease</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Intestinal Neoplasms - blood</topic><topic>Intestinal Neoplasms - diagnosis</topic><topic>Intestinal Neoplasms - mortality</topic><topic>Intestinal Neoplasms - therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - blood</topic><topic>Neuroendocrine Tumors - diagnosis</topic><topic>Neuroendocrine Tumors - mortality</topic><topic>Neuroendocrine Tumors - therapy</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Peptides</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>radionuclide therapy</topic><topic>Stomach Neoplasms - blood</topic><topic>Stomach Neoplasms - diagnosis</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - therapy</topic><topic>Studies</topic><topic>survival</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachu a, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Kolesi ska- wik a, Agnieszka</creatorcontrib><creatorcontrib>I ycka- wieszewska, Ewa</creatorcontrib><creatorcontrib>Sul yc-Bielicka, Violetta</creatorcontrib><creatorcontrib>wik a, Jaros aw B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rogowski, Wojciech</au><au>Wachu a, Ewa</au><au>Lewczuk, Anna</au><au>Kolesi ska- wik a, Agnieszka</au><au>I ycka- wieszewska, Ewa</au><au>Sul yc-Bielicka, Violetta</au><au>wik a, Jaros aw B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>13</volume><issue>12</issue><spage>1069</spage><epage>1079</epage><pages>1069-1079</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with
Y-[DOTA
, D-Phe
, Tyr
]-octreotate.
CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of
Y-[DOTA
, D-Phe
, Tyr
]-octreotate. The primary end point was overall survival.
Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.
Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28095720</pmid><doi>10.2217/fon-2016-0455</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2017-05, Vol.13 (12), p.1069-1079 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1861566955 |
| source | PubMed Central |
| subjects | Biomarkers Biomarkers, Tumor Cancer therapies Chemotherapy chromogranin A Chromogranin A - blood Clinical medicine Cluster analysis Combined Modality Therapy Disease Disease Progression Female Humans Intestinal Neoplasms - blood Intestinal Neoplasms - diagnosis Intestinal Neoplasms - mortality Intestinal Neoplasms - therapy Male Medical prognosis Metastasis Middle Aged Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Neuroendocrine tumors Neuroendocrine Tumors - blood Neuroendocrine Tumors - diagnosis Neuroendocrine Tumors - mortality Neuroendocrine Tumors - therapy Pancreatic Neoplasms - blood Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - mortality Pancreatic Neoplasms - therapy Peptides Prognosis Radiation therapy radionuclide therapy Stomach Neoplasms - blood Stomach Neoplasms - diagnosis Stomach Neoplasms - mortality Stomach Neoplasms - therapy Studies survival Treatment Outcome |
| title | Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A03%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baseline%20chromogranin%20A%20and%20its%20dynamics%20are%20prognostic%20markers%20in%20gastroenteropancreatic%20neuroendocrine%20tumors&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Rogowski,%20Wojciech&rft.date=2017-05-01&rft.volume=13&rft.issue=12&rft.spage=1069&rft.epage=1079&rft.pages=1069-1079&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2016-0455&rft_dat=%3Cproquest_cross%3E2275854923%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-42ede2dca612799c8fc77b4fca8563bc1f9e1d877ad5d014372f1ca00f51bae33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2275854923&rft_id=info:pmid/28095720&rfr_iscdi=true |